Non-exclusive Rebate Agreement for Pankreatin (Open House Model)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Pankreatin (ATC-Code nach WHO: A09AA02)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
Buyer may terminate the Open House process if exclusive rebate agreements are concluded, typically 8-12 months after pu...
Purchase quantities depend on patient numbers, prescription behavior, and pharmacy stocking; no minimum volumes guarant...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Oct 31, 2027
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Oct 2027
- Supply of medicinal products with active ingredient Pankreatin (ATC A09AA02)
- Non-exclusive rebate agreement under §130a Abs. 8 SGB V
Show full summary
Non-exclusive pharmaceutical rebate agreement for Pankreatin (ATC A09AA02) under an Open House model by AOK PLUS. Open to all qualified pharmaceutical entrepreneurs, no exclusivity, no guaranteed minimum volumes. Multiple rolling submission deadlines until 31 Oct 2027. Confidentiality obligations apply. No estimated value provided.
Risks
Buyer may terminate the Open House process if exclusive rebate agreements are concluded, typically 8-12 months after pu...
Purchase quantities depend on patient numbers, prescription behavior, and pharmacy stocking; no minimum volumes guarant...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG
- Must accept Open House model: no individual negotiations, no exclusivity
Eligibility
- Must submit declarations: no exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen) and Russia sanctions compliance (Eigenerklärung Russlandsanktionen)
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive Rebate Agreement for Pankreatin (Open House Model)
Conclusion of non-exclusive discount agreements for medicinal products with active ingredient Pankreatin. No exclusivity, no individual negotiations, open to all interested pharmaceutical entrepreneurs meeting criteria.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Pankreatin (ATC-Code nach WHO: A09AA02)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 28 Aug 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 565192-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
20 / 100
Risk factors
Buyer may terminate the Open House process if exclusive rebate agreements are concluded, typically 8-12 months after pu...
Purchase quantities depend on patient numbers, prescription behavior, and pharmacy stocking; no minimum volumes guarant...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications